Request Demo
Aadi Bioscience to Announce Q3 2024 Results and Corporate Update
15 November 2024
Aadi Bioscience, Inc. revealed today that it will disclose its financial outcomes for the third quarter of 2024 and present recent corporate developments on November 6, 2024. These updates will be accessible on the "Investors & News" page of the Aadi Bioscience website.
Aadi Bioscience is dedicated to the field of precision oncology and specializes in the commercialization of FYARRO®. FYARRO® is intended for the treatment of adult patients diagnosed with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, also known as PEComa. The company aims to provide innovative oncology solutions and improve patient outcomes through targeted therapies.
Aadi Bioscience is dedicated to the field of precision oncology and specializes in the commercialization of FYARRO®. FYARRO® is intended for the treatment of adult patients diagnosed with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, also known as PEComa. The company aims to provide innovative oncology solutions and improve patient outcomes through targeted therapies.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.